|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shi R, Tang YQ and Miao H: Metabolism in
tumor microenvironment: Implications for cancer immunotherapy.
MedComm (2020). 1:47–68. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Pearson-Stuttard J, Papadimitriou N,
Markozannes G, Cividini S, Kakourou A, Gill D, Rizos EC, Monori G,
Ward HA, Kyrgiou M, et al: Type 2 diabetes and cancer: An umbrella
review of observational and mendelian randomization studies. Cancer
Epidemiol Biomarkers Prev. 30:1218–1228. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mili N, Paschou SA, Goulis DG, Dimopoulos
MA, Lambrinoudaki I and Psaltopoulou T: Obesity, metabolic
syndrome, and cancer: Pathophysiological and therapeutic
associations. Endocrine. 74:478–497. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Andersen DK, Korc M, Petersen GM, Eibl G,
Li D, Rickels MR, Chari ST and Abbruzzese JL: Diabetes,
pancreatogenic diabetes, and pancreatic cancer. Diabetes.
66:1103–1110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hu Y, Zeng N, Ge Y, Wang D, Qin X, Zhang
W, Jiang F and Liu Y: Identification of the shared gene signatures
and biological mechanism in type 2 diabetes and pancreatic cancer.
Front Endocrinol (Lausanne). 13(847760)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Escala-Garcia M, Morra A, Canisius S,
Chang-Claude J, Kar S, Zheng W, Bojesen SE, Easton D, Pharoah PDP
and Schmidt MK: Breast cancer risk factors and their effects on
survival: A Mendelian randomisation study. BMC Med.
18(327)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Seino Y and Yabe D: Glucose-dependent
insulinotropic polypeptide and glucagon-like peptide-1: Incretin
actions beyond the pancreas. J Diabetes Investig. 4:108–130.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nauck MA, Quast DR, Wefers J and Meier JJ:
GLP-1 receptor agonists in the treatment of type 2
diabetes-state-of-the-art. Mol Metab. 46(101102)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L,
Sun L, Yang Q, Tang X, Yuan Y, et al: A GLP-1/glucagon
(GCG)/CCK2 receptors tri-agonist provides new therapy
for obesity and diabetes. Br J Pharmacol. 179:4360–4377.
2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bossart M, Wagner M, Elvert R, Evers A,
Hübschle T, Kloeckener T, Lorenz K, Moessinger C, Eriksson O,
Velikyan I, et al: Effects on weight loss and glycemic control with
SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor
triagonist. Cell Metab. 34:59–74.e10. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ligumsky H, Wolf I, Israeli S, Haimsohn M,
Ferber S, Karasik A, Kaufman B and Rubinek T: The peptide-hormone
glucagon-like peptide-1 activates cAMP and inhibits growth of
breast cancer cells. Breast Cancer Res Treat. 132:449–461.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu ZZ, Duan XX, Yuan MC, Yu J, Hu X, Han
X, Lan L, Liu BW, Wang Y and Qin JF: Glucagon-like peptide-1
receptor activation by liraglutide promotes breast cancer through
NOX4/ROS/VEGF pathway. Life Sci. 294(120370)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang Y, Xu F, Liang H, Cai M, Wen X, Li X
and Weng J: Exenatide inhibits the growth of endometrial cancer
Ishikawa xenografts in nude mice. Oncol Rep. 35:1340–1348.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mayendraraj A, Rosenkilde MM and Gasbjerg
LS: GLP-1 and GIP receptor signaling in beta cells-a review of
receptor interactions and co-stimulation. Peptides.
151(170749)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Baggio LL and Drucker DJ: Biology of
incretins: GLP-1 and GIP. Gastroenterology. 132:2131–2157.
2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gribble FM and Reimann F: Signalling in
the gut endocrine axis. Physiol Behav. 176:183–188. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rorsman P and Ashcroft FM: Pancreatic
β-cell electrical activity and insulin secretion: Of mice and men.
Physiol Rev. 98:117–214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nauck MA, Kleine N, Orskov C, Holst JJ,
Willms B and Creutzfeldt W: Normalization of fasting hyperglycaemia
by exogenous glucagon-like peptide 1 (7-36 amide) in type 2
(non-insulin-dependent) diabetic patients. Diabetologia.
36:741–744. 1993.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Drucker DJ: Mechanisms of action and
therapeutic application of glucagon-like peptide-1. Cell Metab.
27:740–756. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Siraj MA, Mundil D, Beca S, Momen A,
Shikatani EA, Afroze T, Sun X, Liu Y, Ghaffari S, Lee W, et al:
Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury
by inhibiting mitochondrial trifunctional protein-α. J Clin Invest.
130:1392–1404. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ussher JR and Drucker DJ: Glucagon-like
peptide 1 receptor agonists: Cardiovascular benefits and mechanisms
of action. Nat Rev Cardiol. 20:463–474. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Montrose-Rafizadeh C, Avdonin P, Garant
MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W and
Bernier M: Pancreatic glucagon-like peptide-1 receptor couples to
multiple G proteins and activates mitogen-activated protein kinase
pathways in Chinese hamster ovary cells. Endocrinology.
140:1132–1140. 1999.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hilger D, Masureel M and Kobilka BK:
Structure and dynamics of GPCR signaling complexes. Nat Struct Mol
Biol. 25:4–12. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Holz GG: Epac: A new cAMP-binding protein
in support of glucagon-like peptide-1 receptor-mediated signal
transduction in the pancreatic beta-cell. Diabetes. 53:5–13.
2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fletcher MM, Halls ML, Christopoulos A,
Sexton PM and Wootten D: The complexity of signalling mediated by
the glucagon-like peptide-1 receptor. Biochem Soc Trans.
44:582–588. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Merola A, Romagnolo A, Rosso M,
Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M,
Maule S, Lopiano L and Espay AJ: Orthostatic hypotension in
Parkinson's disease: Does it matter if asymptomatic? Parkinsonism
Relat Disord. 33:65–71. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liu L, Rashid M and Wess J: Regulation of
GLP-1 and glucagon receptor function by β-arrestins in
metabolically important cell types. Biochemistry. 64:978–986.
2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zaïmia N, Obeid J, Varrault A, Sabatier J,
Broca C, Gilon P, Costes S, Bertrand G and Ravier MA: GLP-1 and GIP
receptors signal through distinct β-arrestin 2-dependent pathways
to regulate pancreatic β cell function. Cell Rep.
42(113326)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Holmes B, Benavides-Serrato A, Freeman RS,
Landon KA, Bashir T, Nishimura RN and Gera J: mTORC2/AKT/HSF1/HuR
constitute a feed-forward loop regulating rictor expression and
tumor growth in glioblastoma. Oncogene. 37:732–743. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y,
Zhang C and Gao J: Glucagon-like peptide-1 receptor: Mechanisms and
advances in therapy. Signal Transduct Target Ther.
9(234)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gasbjerg LS, Helsted MM, Hartmann B,
Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng
AR, Bergmann NC, et al: Separate and combined glucometabolic
effects of endogenous glucose-dependent insulinotropic polypeptide
and glucagon-like peptide 1 in healthy individuals. Diabetes.
68:906–917. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mcintosh CH, Widenmaier S and Kim SJ:
Glucose-dependent insulinotropic polypeptide signaling in
pancreatic β-cells and adipocytes. J Diabetes Investig. 3:96–106.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ding WG and Gromada J: Protein kinase
A-dependent stimulation of exocytosis in mouse pancreatic
beta-cells by glucose-dependent insulinotropic polypeptide.
Diabetes. 46:615–621. 1997.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kagdi S, Lyons SA and Beaudry JL: The
interplay of glucose-dependent insulinotropic polypeptide in
adipose tissue. J Endocrinol. 261(e230361)2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ehses JA, Pelech SL, Pederson RA and
McIntosh CH: Glucose-dependent insulinotropic polypeptide activates
the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent
protein kinase/Rap1-mediated pathway. J Biol Chem. 277:37088–37097.
2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Widenmaier SB, Ao Z, Kim SJ, Warnock G and
McIntosh CH: Suppression of p38 MAPK and JNK via Akt-mediated
inhibition of apoptosis signal-regulating kinase 1 constitutes a
core component of the beta-cell pro-survival effects of
glucose-dependent insulinotropic polypeptide. J Biol Chem.
284:30372–30382. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kim SJ, Winter K, Nian C, Tsuneoka M, Koda
Y and McIntosh CH: Glucose-dependent insulinotropic polypeptide
(GIP) stimulation of pancreatic beta-cell survival is dependent
upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)
signaling, inactivation of the forkhead transcription factor Foxo1,
and down-regulation of bax expression. J Biol Chem.
280:22297–22307. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kim SJ, Nian C, Widenmaier S and McIntosh
CH: Glucose-dependent insulinotropic polypeptide-mediated
up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is
coordinated by cyclic AMP (cAMP) response element binding protein
(CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol.
28:1644–1656. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Asmar M, Asmar A, Simonsen L, Gasbjerg LS,
Sparre-Ulrich AH, Rosenkilde MM, Hartmann B, Dela F, Holst JJ and
Bülow J: The Gluco- and liporegulatory and vasodilatory effects of
glucose-dependent insulinotropic polypeptide (GIP) are abolished by
an antagonist of the human GIP receptor. Diabetes. 66:2363–2371.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Getty-Kaushik L, Song DH, Boylan MO,
Corkey BE and Wolfe MM: Glucose-dependent insulinotropic
polypeptide modulates adipocyte lipolysis and reesterification.
Obesity (Silver Spring). 14:1124–1131. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
No authors listed. Correction to:
‘Glucose-dependent insulinotropic polypeptide in incretin
physiology: Role in health and disease’. Endocr Rev.
46(954)2025.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Thorens B: Neuronal regulation of glucagon
secretion and gluconeogenesis. J Diabetes Investig. 13:599–607.
2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lee YH, Wang MY, Yu XX and Unger RH:
Glucagon is the key factor in the development of diabetes.
Diabetologia. 59:1372–1375. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Capozzi ME, D'Alessio DA and Campbell JE:
. The past, present, and future physiology and pharmacology of
glucagon. Cell Metab. 34:1654–1674. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li K, Qiu C, Sun P, Liu DC, Wu TJ, Wang K,
Zhou YC, Chang XA, Yin Y, Chen F, et al: Ets1-mediated acetylation
of FoxO1 Is critical for gluconeogenesis regulation during
feed-fast cycles. Cell Rep. 26:2998–3010.e5. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Dominy JE Jr, Lee Y, Jedrychowski MP, Chim
H, Jurczak MJ, Camporez JP, Ruan HB, Feldman J, Pierce K,
Mostoslavsky R, et al: The deacetylase Sirt6 activates the
acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol
Cell. 48:900–913. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Gertler AA and Cohen HY: SIRT6, a protein
with many faces. Biogerontology. 14:629–639. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Harney JA and Rodgers RL: Insulin-like
stimulation of cardiac fuel metabolism by physiological levels of
glucagon: Involvement of PI3K but not cAMP. Am J Physiol Endocrinol
Metab. 295:E155–E161. 2008.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hansen LH, Gromada J, Bouchelouche P,
Whitmore T, Jelinek L, Kindsvogel W and Nishimura E:
Glucagon-mediated Ca2+ signaling in BHK cells expressing cloned
human glucagon receptors. Am J Physiol. 274:C1552–C1562.
1998.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ozcan L, Wong CC, Li G, Xu T, Pajvani U,
Park SK, Wronska A, Chen BX, Marks AR, Fukamizu A, et al: Calcium
signaling through CaMKII regulates hepatic glucose production in
fasting and obesity. Cell Metab. 15:739–751. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Liu Y, Dentin R, Chen D, Hedrick S,
Ravnskjaer K, Schenk S, Milne J, Meyers DJ, Cole P, Yates J III, et
al: A fasting inducible switch modulates gluconeogenesis via
activator/coactivator exchange. Nature. 456:269–273.
2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wondisford AR, Xiong L, Chang E, Meng S,
Meyers DJ, Li M, Cole PA and He L: Control of Foxo1 gene expression
by co-activator P300. J Biol Chem. 289:4326–4333. 2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Guzman CB, Zhang XM, Liu R, Regev A,
Shankar S, Garhyan P, Pillai SG, Kazda C, Chalasani N and Hardy TA:
Treatment with LY2409021, a glucagon receptor antagonist, increases
liver fat in patients with type 2 diabetes. Diabetes Obes Metab.
19:1521–1528. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shi T, Fan GQ and Xiao SD: SIRT3 reduces
lipid accumulation via AMPK activation in human hepatic cells. J
Dig Dis. 11:55–62. 2010.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Perry RJ, Zhang D, Guerra MT, Brill AL,
Goedeke L, Nasiri AR, Rabin-Court A, Wang Y, Peng L, Dufour S, et
al: Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic
lipolysis. Nature. 579:279–283. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Müller TD, Finan B, Clemmensen C, DiMarchi
RD and Tschöp MH: The new biology and pharmacology of glucagon.
Physiol Rev. 97:721–766. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Kim H, Mendez R, Chen X, Fang D and Zhang
K: Lysine acetylation of CREBH regulates fasting-induced hepatic
lipid metabolism. Mol Cell Biol. 35:4121–4134. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Rodgers RL: Glucagon, cyclic AMP, and
hepatic glucose mobilization: A half-century of uncertainty.
Physiol Rep. 10(e15263)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wang H, Zhao M, Sud N, Christian P, Shen
J, Song Y, Pashaj A, Zhang K, Carr T and Su Q: Glucagon regulates
hepatic lipid metabolism via cAMP and Insig-2 signaling:
Implication for the pathogenesis of hypertriglyceridemia and
hepatic steatosis. Sci Rep. 6(32246)2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Winther JB and Holst JJ: Glucagon agonism
in the treatment of metabolic diseases including type 2 diabetes
mellitus and obesity. Diabetes Obes Metab. 26:3501–3512.
2024.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wawrzak-Pienkowska K, Pienkowski T,
Golonko A, Krupa A, Warpechowski M, Plonski AF, Mojsak P, Daniluk
J, Dabrowski A and Kurek K: Incretin signaling at the crossroads of
metabolism, inflammation, and tumorigenesis: Implications for
obesity patients. Eur J Pharmacol. 1007(178290)2025.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Miousse IR: GLP-1 receptor agonists in the
context of cancer: The road ahead. Am J Physiol Cell Physiol.
328:C1822–C1828. 2025.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Spezani R and Mandarim-de-Lacerda CA: The
current significance and prospects for the use of dual receptor
agonism GLP-1/Glucagon. Life Sci. 288(120188)2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Zhou J, Cai X, Huang X, Dai Y, Sun L,
Zhang B, Yang B, Lin H, Huang W and Qian H: A novel glucagon-like
peptide-1/glucagon receptor dual agonist exhibits weight-lowering
and diabetes-protective effects. Eur J Med Chem. 138:1158–1169.
2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Del Prato S, Gallwitz B, Holst JJ and
Meier JJ: The incretin/glucagon system as a target for
pharmacotherapy of obesity. Obes Rev. 23(e13372)2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Parker VER, Robertson D, Erazo-Tapia E,
Havekes B, Phielix E, de Ligt M, Roumans KHM, Mevenkamp J, Sjoberg
F, Schrauwen-Hinderling VB, et al: Cotadutide promotes
glycogenolysis in people with overweight or obesity diagnosed with
type 2 diabetes. Nat Metab. 5:2086–2093. 2023.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Sanchez-Pino MD, Gilmore LA, Ochoa AC and
Brown JC: Obesity-associated myeloid immunosuppressive cells, key
players in cancer risk and response to immunotherapy. Obesity
(Silver Spring). 29:944–953. 2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Kong W, Deng B, Shen X, John C, Haag J,
Sinha N, Lee D, Sun W, Chen S, Zhang H, et al: Tirzepatide as an
innovative treatment strategy in a pre-clinical model of
obesity-driven endometrial cancer. Gynecol Oncol. 191:116–123.
2024.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Marathe SJ, Grey EW, Bohm MS, Joseph SC,
Ramesh AV, Cottam MA, Idrees K, Wellen KE, Hasty AH, Rathmell JC
and Makowski L: Incretin triple agonist retatrutide (LY3437943)
alleviates obesity-associated cancer progression. NPJ Metab Health
Dis. 3(10)2025.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Huang X, Liu J, Peng G, Lu M, Zhou Z,
Jiang N and Yan Z: Gut hormone multi-agonists for the treatment of
type 2 diabetes and obesity: Advances and challenges. J Endocrinol.
262(e230404)2024.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Valencia-Rincón E, Rai R, Chandra V and
Wellberg EA: GLP-1 receptor agonists and cancer: Current clinical
evidence and translational opportunities for preclinical research.
J Clin Invest. 135(e194743)2025.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wang L, Xu R, Kaelber DC and Berger NA:
Glucagon-like peptide 1 receptor agonists and 13 obesity-associated
cancers in patients with type 2 diabetes. JAMA Netw Open.
7(e2421305)2024.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ko A, Chang YC, Bahar F, Wang TH,
Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, et al: Risk
for cancer with glucagon-like peptide-1 receptor agonists and dual
agonists: A systematic review and meta-analysis. Ann Intern Med.
179:216–229. 2026.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Wang L, Wang W, Kaelber DC, Xu R and
Berger NA: GLP-1 receptor agonists and colorectal cancer risk in
drug-naive patients with type 2 diabetes, with and without
overweight/obesity. JAMA Oncol. 10:256–258. 2024.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Silverii GA, Marinelli C, Bettarini C, Del
Vescovo GG, Monami M and Mannucci E: GLP-1 receptor agonists and
the risk for cancer: A meta-analysis of randomized controlled
trials. Diabetes Obes Metab. 27:4454–4468. 2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yamanouchi D: The roles of incretin
hormones GIP and GLP-1 in metabolic and cardiovascular health: A
comprehensive review. Int J Mol Sci. 27(27)2025.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ji L, He X, Min X, Yang H, Wu W, Xu H,
Chen J and Mei A: Glucagon-like peptide-1 receptor agonists in
neoplastic diseases. Front Endocrinol (Lausanne).
15(1465881)2024.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lin A, Ding Y, Li Z, Jiang A, Liu Z, Wong
HZH, Cheng Q, Zhang J and Luo P: Glucagon-like peptide 1 receptor
agonists and cancer risk: advancing precision medicine through
mechanistic understanding and clinical evidence. Biomark Res.
13(50)2025.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Elkind-Hirsch KE, Chappell N, Shaler D,
Storment J and Bellanger D: Liraglutide 3 mg on weight, body
composition, and hormonal and metabolic parameters in women with
obesity and polycystic ovary syndrome: A randomized
placebo-controlled-phase 3 study. Fertil Steril. 118:371–381.
2022.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Sandsdal RM, Juhl CR, Jensen SBK, Lundgren
JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen
JB, et al: Combination of exercise and GLP-1 receptor agonist
treatment reduces severity of metabolic syndrome, abdominal
obesity, and inflammation: A randomized controlled trial.
Cardiovasc Diabetol. 22(41)2023.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Muzurović EM, Volčanšek Š, Tomšić KZ,
Janež A, Mikhailidis DP, Rizzo M and Mantzoros CS: Glucagon-like
peptide-1 receptor agonists and dual glucose-dependent
insulinotropic polypeptide/glucagon-like peptide-1 receptor
agonists in the treatment of obesity/metabolic syndrome,
prediabetes/diabetes and non-alcoholic fatty liver disease-current
evidence. J Cardiovasc Pharmacol Ther.
27(10742484221146371)2022.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Pandey S, Mangmool S, Madreiter-Sokolowski
CT, Wichaiyo S, Luangmonkong T and Parichatikanond W: Exendin-4
protects against high glucose-induced mitochondrial dysfunction and
oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1
receptor/Epac/Akt signaling. Eur J Pharmacol.
954(175896)2023.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Yagi T, Kubota E, Koyama H, Tanaka T,
Kataoka H, Imaeda K and Joh T: Glucagon promotes colon cancer cell
growth via regulating AMPK and MAPK pathways. Oncotarget.
9:10650–10664. 2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Carugno J, Marbin SJ, LaganÀ AS, Vitale
SG, Alonso L, DI Spiezio Sardo A and Haimovich S: New development
on hysteroscopy for endometrial cancer diagnosis: State of the art.
Minerva Med. 112:12–19. 2021.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Kundu M, Butti R, Panda VK, Malhotra D,
Das S, Mitra T, Kapse P, Gosavi SW and Kundu GC: Modulation of the
tumor microenvironment and mechanism of immunotherapy-based drug
resistance in breast cancer. Mol Cancer. 23(92)2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
De Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Li Z, Pai R, Gupta S, Currenti J, Guo W,
Di Bartolomeo A, Feng H, Zhang Z, Li Z, Liu L, et al: Presence of
onco-fetal neighborhoods in hepatocellular carcinoma is associated
with relapse and response to immunotherapy. Nat Cancer. 5:167–186.
2024.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Ward PS and Thompson CB: Metabolic
reprogramming: A cancer hallmark even warburg did not anticipate.
Cancer Cell. 21:297–308. 2012.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Ghesquière B, Wong BW, Kuchnio A and
Carmeliet P: Metabolism of stromal and immune cells in health and
disease. Nature. 511:167–176. 2014.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18(157)2019.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Colegio OR, Chu NQ, Szabo AL, Chu T,
Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC,
Phillips GM, et al: Functional polarization of tumour-associated
macrophages by tumour-derived lactic acid. Nature. 513:559–563.
2014.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Macintyre AN, Gerriets VA, Nichols AG,
Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen
BJ, Hale LP and Rathmell JC: The glucose transporter Glut1 is
selectively essential for CD4 T cell activation and effector
function. Cell Metab. 20:61–72. 2014.PubMed/NCBI View Article : Google Scholar
|
|
95
|
van Vlerken-Ysla L, Tyurina YY, Kagan VE
and Gabrilovich DI: Functional states of myeloid cells in cancer.
Cancer Cell. 41:490–504. 2023.PubMed/NCBI View Article : Google Scholar
|
|
96
|
You S, Li S, Zeng L, Song J, Li Z, Li W,
Ni H, Xiao X, Deng W, Li H, et al: Lymphatic-localized Treg-mregDC
crosstalk limits antigen trafficking and restrains anti-tumor
immunity. Cancer Cell. 42:1415–1433.e12. 2024.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X
and Zhuang A: Amino acid metabolism reprogramming: Shedding new
light on T cell anti-tumor immunity. J Exp Clin Cancer Res.
42(291)2023.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lucente D, Bellino S and La Salvia A:
GLP-1 receptor agonists in solid tumour therapy: Exploring their
anticancer potential and underlying molecular pathways. Genes
(Basel). 16(1352)2025.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kounatidis D, Vallianou NG, Karampela I,
Rebelos E, Kouveletsou M, Dalopoulos V, Koufopoulos P,
Diakoumopoulou E, Tentolouris N and Dalamaga M: Anti-diabetic
therapies and cancer: From bench to bedside. Biomolecules.
14(1479)2024.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Ostroumov D, Fekete-Drimusz N, Saborowski
M, Kühnel F and Woller N: CD4 and CD8 T lymphocyte interplay in
controlling tumor growth. Cell Mol Life Sci. 75:689–713.
2018.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Farhood B, Najafi M and Mortezaee K:
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A
review. J Cell Physiol. 234:8509–8521. 2019.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wei J, Zheng W, Chapman NM, Geiger TL and
Chi H: T cell metabolism in homeostasis and cancer immunity. Curr
Opin Biotechnol. 68:240–250. 2021.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Deng S, Chen Z and Shi Y: Roles of
glucagon-like peptide 1 receptor agonists in immune cell biology
and autoimmune/autoinflammatory diseases. Cell Biosci.
15(137)2025.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Ben Nasr M, Usuelli V, Dellepiane S,
Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y,
Balasubramanian HB, et al: Glucagon-like peptide 1 receptor is a T
cell-negative costimulatory molecule. Cell Metab. 36:1302–1319.e12.
2024.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Moschovaki Filippidou F, Kirsch AH, Thelen
M, Kétszeri M, Artinger K, Aringer I, Schabhüttl C, Mooslechner AA,
Frauscher B, Pollheimer M, et al: Glucagon-like peptide-1 receptor
agonism improves nephrotoxic serum nephritis by inhibiting T-cell
proliferation. Am J Pathol. 190:400–411. 2020.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Wong CK, Yusta B, Koehler JA, Baggio LL,
McLean BA, Matthews D, Seeley RJ and Drucker DJ: Divergent roles
for the gut intraepithelial lymphocyte GLP-1R in control of
metabolism, microbiota, and T cell-induced inflammation. Cell
Metab. 34:1514–1531.e7. 2022.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Wong CK and Drucker DJ: Antiinflammatory
actions of glucagon-like peptide-1-based therapies beyond metabolic
benefits. J Clin Invest. 135(e194751)2025.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Stanisavljevic I, Pavlovic S, Simovic
Markovic B, Jurisevic M, Krajnovic T, Mijatovic S, Spasojevic M,
Mitrovic S, Corovic I and Jovanovic I: Semaglutide decelerates the
growth and progression of breast cancer by enhancing the acquired
antitumor immunity. Biomed Pharmacother. 181(117668)2024.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Chen D, Li Q, Liang H, Huang L, Zhou H,
Zheng X and Wang Z: Exenatide enhanced the antitumor efficacy on
PD-1 blockade by the attenuation of neutrophil extracellular traps.
Biochem Biophys Res Commun. 619:97–103. 2022.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Chen D, Liang H, Huang L, Zhou H and Wang
Z: Liraglutide enhances the effect of checkpoint blockade in lung
and liver cancers through the inhibition of neutrophil
extracellular traps. FEBS Open Bio. 14:1365–1377. 2024.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Pachimatla AG, Fitzgerald B, Ogidigo J,
Bhatia M, Smith RJ Jr, Ratnakaram K, Kalvapudi S, Vedire Y,
Washington D, Vethanayagam Rr R, et al: Glucagon-like peptide-1
receptor agonism improves lung cancer outcomes and tumor growth
control. JCI insight. 10(e195484)2025.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Teijeira Á, Garasa S, Gato M, Alfaro C,
Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria
I, et al: CXCR1 and CXCR2 chemokine receptor agonists produced by
tumors induce neutrophil extracellular traps that interfere with
immune cytotoxicity. Immunity. 52:856–871.e8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Kaltenmeier C, Yazdani HO, Morder K,
Geller DA, Simmons RL and Tohme S: Neutrophil extracellular traps
promote T cell exhaustion in the tumor microenvironment. Front
Immunol. 12(785222)2021.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Guo J, Shu T, Zhang H, Huang N, Ren J, Lin
L, Wu J, Wang Y, Huang Z, Bin J, et al: A combined model of serum
neutrophil extracellular traps, CD8+ T cells, and tumor
proportion score provides better prediction of PD-1 inhibitor
efficacy in patients with NSCLC. FEBS J. 291:3403–3416.
2024.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Coënon L, Geindreau M, Ghiringhelli F,
Villalba M and Bruchard M: Natural Killer cells at the frontline in
the fight against cancer. Cell Death Dis. 15(614)2024.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Chen S, Zhu H and Jounaidi Y:
Comprehensive snapshots of natural killer cells functions,
signaling, molecular mechanisms and clinical utilization. Signal
Transduct Target Ther. 9(302)2024.PubMed/NCBI View Article : Google Scholar
|
|
118
|
De Barra C, Khalil M, Mat A, O'Donnell C,
Shaamile F, Brennan K, O'Shea D and Hogan AE: Glucagon-like
peptide-1 therapy in people with obesity restores natural killer
cell metabolism and effector function. Obesity (Silver Spring).
31:1787–1797. 2023.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Ogura K, Sato-Matsushita M, Yamamoto S,
Hori T, Sasahara M, Iwakura Y, Saiki I, Tahara H and Hayakawa Y: NK
cells control tumor-promoting function of neutrophils in mice.
Cancer Immunol Res. 6:348–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Wang Y, Guo Z, Xu A, Fu Z, Hou Y, Tang K,
Li J, Zhao F and Chen L: Mechanistic insights into IL-6-mediated NK
cell dysfunction in NSCLC via the IRE1α-XBP1s-STAT3-UBE2S axis. NPJ
Precis Oncol. 9(361)2025.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang
C, Wu J and Wei J: Liraglutide activates nature killer
cell-mediated antitumor responses by inhibiting IL-6/STAT3
signaling in hepatocellular carcinoma. Transl Oncol.
14(100872)2021.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Li S, Yu J, Huber A, Kryczek I, Wang Z,
Jiang L, Li X, Du W, Li G, Wei S, et al: Metabolism drives
macrophage heterogeneity in the tumor microenvironment. Cell Rep.
39(110609)2022.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Laoui D, Van Overmeire E, Di Conza G,
Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe
E, Elkrim Y, et al: Tumor hypoxia does not drive differentiation of
tumor-associated macrophages but rather fine-tunes the M2-like
macrophage population. Cancer Res. 74:24–30. 2014.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Li M, Yang Y, Xiong L, Jiang P, Wang J and
Li C: Metabolism, metabolites, and macrophages in cancer. J Hematol
Oncol. 16(80)2023.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Cassetta L and Pollard JW: Targeting
macrophages: Therapeutic approaches in cancer. Nat Rev Drug Discov.
17:887–904. 2018.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Basak U, Sarkar T, Mukherjee S,
Chakraborty S, Dutta A, Dutta S, Nayak D, Kaushik S, Das T and Sa
G: Tumor-associated macrophages: An effective player of the tumor
microenvironment. Front Immunol. 14(1295257)2023.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Meurot C, Martin C, Sudre L, Breton J,
Bougault C, Rattenbach R, Bismuth K, Jacques C and Berenbaum F:
Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts
analgesic, anti-inflammatory and anti-degradative actions in
osteoarthritis. Sci Rep. 12(1567)2022.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Vinué Á, Navarro J, Herrero-Cervera A,
García-Cubas M, Andrés-Blasco I, Martínez-Hervás S, Real JT, Ascaso
JF and González-Navarro H: The GLP-1 analogue lixisenatide
decreases atherosclerosis in insulin-resistant mice by modulating
macrophage phenotype. Diabetologia. 60:1801–1812. 2017.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Shiraishi D, Fujiwara Y, Komohara Y,
Mizuta H and Takeya M: Glucagon-like peptide-1 (GLP-1) induces M2
polarization of human macrophages via STAT3 activation. Biochem
Biophys Res Commun. 425:304–308. 2012.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Yang L, Chen L, Li D, Xu H and Chen J, Min
X, He M, Wu T, Zhong J, Yang H and Chen J: Effect of GLP-1/GLP-1R
on the polarization of macrophages in the occurrence and
development of atherosclerosis. Mediators Inflamm.
2021(5568159)2021.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Hogan AE, Gaoatswe G, Lynch L, Corrigan
MA, Woods C, O'Connell J and O'Shea D: Glucagon-like peptide 1
analogue therapy directly modulates innate immune-mediated
inflammation in individuals with type 2 diabetes mellitus.
Diabetologia. 57:781–784. 2014.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Wang S, Wang J, Chen Z, Luo J, Guo W, Sun
L and Lin L: Targeting M2-like tumor-associated macrophages is a
potential therapeutic approach to overcome antitumor drug
resistance. NPJ Precis Oncol. 8(31)2024.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Bruen R, Curley S, Kajani S, Crean D,
O'Reilly ME, Lucitt MB, Godson CG, McGillicuddy FC and Belton O:
Liraglutide dictates macrophage phenotype in apolipoprotein E null
mice during early atherosclerosis. Cardiovasc Diabetol.
16(143)2017.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Salkeni MA and Naing A: Interleukin-10 in
cancer immunotherapy: From bench to bedside. Trends Cancer.
9:716–725. 2023.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Bułdak Ł, Bołdys A, Skudrzyk E, Machnik G
and Okopień B: Liraglutide therapy in obese patients alters
macrophage phenotype and decreases their tumor necrosis factor
alpha release and oxidative stress markers-a pilot study.
Metabolites. 14(554)2024.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Rannikko JH and Hollmén M: Clinical
landscape of macrophage-reprogramming cancer immunotherapies. Br J
Cancer. 131:627–640. 2024.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Heras-Murillo I, Adán-Barrientos I, Galán
M, Wculek SK and Sancho D: Dendritic cells as orchestrators of
anticancer immunity and immunotherapy. Nat Rev Clin Oncol.
21:257–277. 2024.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Xiao Z, Wang R, Wang X, Yang H, Dong J, He
X, Yang Y, Guo J, Cui J and Zhou Z: Impaired function of dendritic
cells within the tumor microenvironment. Front Immunol.
14(1213629)2023.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Liu Z, Dai H, Cui X, Liu Y and Dong Z:
Importance of B cells (review). Int J Mol Med. 57(2)2026.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Fridman WH, Meylan M, Petitprez F, Sun CM,
Italiano A and Sautès-Fridman C: B cells and tertiary lymphoid
structures as determinants of tumour immune contexture and clinical
outcome. Nat Rev Clin Oncol. 19:441–457. 2022.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Yang Y, Chen X, Pan J, Ning H, Zhang Y, Bo
Y, Ren X, Li J, Qin S, Wang D, et al: Pan-cancer single-cell
dissection reveals phenotypically distinct B cell subtypes. Cell.
187:4790–4811.e22. 2024.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Sakimura C, Tanaka H, Okuno T, Hiramatsu
S, Muguruma K, Hirakawa K, Wanibuchi H and Ohira M: B cells in
tertiary lymphoid structures are associated with favorable
prognosis in gastric cancer. J Surg Res. 215:74–82. 2017.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Baggio LL, Holland D, Wither J and Drucker
DJ: Lymphocytic infiltration and immune activation in
metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice.
Diabetes. 55:1562–1570. 2006.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH,
Deng K and Yang JL: Lipid metabolic reprogramming in tumor
microenvironment: From mechanisms to therapeutics. J Hematol Oncol.
16(103)2023.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Moiz A, Filion KB, Tsoukas MA, Yu OHY,
Peters TM and Eisenberg MJ: The expanding role of GLP-1 receptor
agonists: A narrative review of current evidence and future
directions. EClinicalMedicine. 86(103363)2025.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Shigeoka T, Nomiyama T, Kawanami T,
Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N,
Tanabe M, et al: Activation of overexpressed glucagon-like
peptide-1 receptor attenuates prostate cancer growth by inhibiting
cell cycle progression. J Diabetes Investig. 11:1137–1149.
2020.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Eftekhari S, Montazeri H and Tarighi P:
Synergistic anti-tumor effects of Liraglutide, a glucagon-like
peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate
cancer cell line. Eur J Pharmacol. 878(173102)2020.PubMed/NCBI View Article : Google Scholar
|
|
148
|
He W and Li J: Exendin-4 enhances
radiation response of prostate cancer. Prostate. 78:1125–1133.
2018.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Krause GC, Lima KG, Dias HB, da Silva EFG,
Haute GV, Basso BS, Gassen RB, Marczak ES, Nunes RSB and de
Oliveira JR: Liraglutide, a glucagon-like peptide-1 analog, induce
autophagy and senescence in HepG2 cells. Eur J Pharmacol.
809:32–41. 2017.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Alanteet AA, Attia HA, Shaheen S, Alfayez
M and Alshanawani B: Anti-proliferative activity of glucagon-like
peptide-1 receptor agonist on obesity-associated breast cancer: The
impact on modulating adipokines' expression in adipocytes and
cancer cells. Dose Response. 19(1559325821995651)2021.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Zhao H, Wei R, Wang L, Tian Q, Tao M, Ke
J, Liu Y, Hou W, Zhang L, Yang J and Hong T: Activation of
glucagon-like peptide-1 receptor inhibits growth and promotes
apoptosis of human pancreatic cancer cells in a cAMP-dependent
manner. Am J Physiol Endocrinol Metab. 306:E1431–E1441.
2014.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Koehler JA, Kain T and Drucker DJ:
Glucagon-like peptide-1 receptor activation inhibits growth and
augments apoptosis in murine CT26 colon cancer cells.
Endocrinology. 152:3362–3372. 2011.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu
X, Zhang Z, Yang S and Xiao M: Extracellular matrix remodeling in
tumor progression and immune escape: From mechanisms to treatments.
Mol Cancer. 22(48)2023.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Saatci O, Kaymak A, Raza U, Ersan PG,
Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari
SA, et al: Targeting lysyl oxidase (LOX) overcomes chemotherapy
resistance in triple negative breast cancer. Nat Commun.
11(2416)2020.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Scavo MP, Lisco G, Depalo N, Rizzi F,
Volpe S, Arrè V, Carrieri L, Notarnicola M, De Nunzio V, Curri ML,
et al: Semaglutide modulates extracellular matrix production of
LX-2 cells via exosomes and improves metabolic
dysfunction-associated steatotic liver disease (MASLD). Int J Mol
Sci. 25(1493)2024.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Robinson E, Cassidy RS, Tate M, Zhao Y,
Lockhart S, Calderwood D, Church R, McGahon MK, Brazil DP,
McDermott BJ, et al: Exendin-4 protects against post-myocardial
infarction remodelling via specific actions on inflammation and the
extracellular matrix. Basic Res Cardiol. 110(20)2015.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Huang L, Lin T, Shi M, Chen X and Wu P:
Liraglutide suppresses production of extracellular matrix proteins
and ameliorates renal injury of diabetic nephropathy by enhancing
Wnt/β-catenin signaling. Am J Physiol Renal Physiol. 319:F458–F468.
2020.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Liu J, Li X, Lu S, Zheng X, Zhang X and
Zhao W: Glucagon-like peptide-1 (GLP-1) improved diabetic lung
fibrosis via AMPK and microRNA-27a (miR-27a). Ann Transl Med.
9(492)2021.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Song N, Xu H, Liu J, Zhao Q, Chen H, Yan
Z, Yang R, Luo Z, Liu Q, Ouyang J, et al: Design of a highly potent
GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis. Acta
Pharm Sin B. 12:2443–2461. 2022.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Yang F, Luo X, Li J, Lei Y, Zeng F, Huang
X, Lan Y and Liu R: Application of glucagon-like peptide-1 receptor
antagonists in fibrotic diseases. Biomed Pharmacother.
152(113236)2022.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Cardoso LEM, Marinho TS, Martins FF,
Aguila MB and Mandarim-de-Lacerda CA: Treatment with semaglutide, a
GLP-1 receptor agonist, improves extracellular matrix remodeling in
the pancreatic islet of diet-induced obese mice. Life Sci.
319(121502)2023.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Du H, Xu T, Yu S, Wu S and Zhang J:
Mitochondrial metabolism and cancer therapeutic innovation. Signal
Transduct Target Ther. 10(245)2025.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Patel PS, Castelow C, Patel DS,
Bhattacharya SK, Kuscu C, Kuscu C, Makowski L, Eason JD and Bajwa
A: Mitochondrial role in oncogenesis and potential chemotherapeutic
strategy of mitochondrial infusion in breast cancer. Int J Mol Sci.
23(12993)2022.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Zhang Y, Yan H, Wei Y and Wei X: Decoding
mitochondria's role in immunity and cancer therapy. Biochim Biophys
Acta Rev Cancer. 1879(189107)2024.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Kiweler N, Delbrouck C, Pozdeev VI, Neises
L, Soriano-Baguet L, Eiden K, Xian F, Benzarti M, Haase L, Koncina
E, et al: Mitochondria preserve an autarkic one-carbon cycle to
confer growth-independent cancer cell migration and metastasis. Nat
Commun. 13(2699)2022.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Morales PE, Torres G, Sotomayor-Flores C,
Peña-Oyarzún D, Rivera-Mejías P, Paredes F and Chiong M: GLP-1
promotes mitochondrial metabolism in vascular smooth muscle cells
by enhancing endoplasmic reticulum-mitochondria coupling. Biochem
Biophys Res Commun. 446:410–416. 2014.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Liao P, Yang D, Liu D and Zheng Y: GLP-1
and ghrelin attenuate high glucose/high lipid-induced apoptosis and
senescence of human microvascular endothelial cells. Cell Physiol
Biochem. 44:1842–1855. 2017.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Zhang L, Tian J, Diao S, Zhang G, Xiao M
and Chang D: GLP-1 receptor agonist liraglutide protects
cardiomyocytes from IL-1β-induced metabolic disturbance and
mitochondrial dysfunction. Chem Biol Interact.
332(109252)2020.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Wang C, Li Q, Wang W, Guo L, Guo C, Sun Y
and Zhang J: GLP-1 contributes to increases in PGC-1α expression by
downregulating miR-23a to reduce apoptosis. Biochem Biophys Res
Commun. 466:33–99. 2015.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Yamada S, Ogura Y, Inoue K, Tanabe J,
Sugaya T, Ohata K, Nagai Y, Natsuki Y, Hoshino S, Watanabe S, et
al: Effect of GLP-1 receptor agonist, liraglutide, on muscle in
spontaneously diabetic torii fatty rats. Mol Cell Endocrinol.
539(111472)2022.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Li X, Luo W, Tang Y, Wu J, Zhang J, Chen
S, Zhou L, Tao Y, Tang Y, Wang F, et al: Semaglutide attenuates
doxorubicin-induced cardiotoxicity by ameliorating BNIP3-mediated
mitochondrial dysfunction. Redox Biol. 72(103129)2024.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Old VJ, Davies MJ, Papamargaritis D,
Choudhary P and Watson EL: The effects of glucagon-like peptide-1
receptor agonists on mitochondrial function within skeletal muscle:
A systematic review. J Cachexia Sarcopenia Muscle.
16(e13677)2025.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Luna-Marco C, de Marañon AM, Hermo-Argibay
A, Rodriguez-Hernandez Y, Hermenejildo J, Fernandez-Reyes M,
Apostolova N, Vila J, Sola E, Morillas C, et al: Effects of GLP-1
receptor agonists on mitochondrial function, inflammatory markers
and leukocyte-endothelium interactions in type 2 diabetes. Redox
Biol. 66(102849)2023.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Krause GC, Lima KG, Levorse V, Haute GV,
Gassen RB, Garcia MC, Pedrazza L, Donadio MVF, Luft C and de
Oliveira JR: Exenatide induces autophagy and prevents the cell
regrowth in HepG2 cells. EXCLI J. 18:540–548. 2019.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Wang L, Berger NA, Kaelber DC and Xu R:
Association of GLP-1 receptor agonists and hepatocellular carcinoma
incidence and hepatic decompensation in patients with type 2
diabetes. Gastroenterology. 167:689–703. 2024.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Rothman SM, Yin H, Yu OHY, Pollak M and
Azoulay L: Incretin-based drugs and the incidence of endometrial
cancer among people with type 2 diabetes: Active comparator
new-user design. Drug Saf. 48:1023–1033. 2025.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Kolotkin RL, Fujioka K, Wolden ML, Brett
JH and Bjorner JB: Improvements in health-related quality of life
with liraglutide 3.0 mg compared with placebo in weight management.
Clin Obes. 6:233–242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Wharton S, Calanna S, Davies M, Dicker D,
Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA
and Pedersen SD: Gastrointestinal tolerability of once-weekly
semaglutide 2.4 mg in adults with overweight or obesity, and the
relationship between gastrointestinal adverse events and weight
loss. Diabetes Obes Metab. 24:94–105. 2022.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Dankner R, Murad H, Agay N, Olmer L and
Freedman LS: Glucagon-like peptide-1 receptor agonists and
pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw
Open. 7(e2350408)2024.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Monami M, Nreu B, Scatena A, Cresci B,
Andreozzi F, Sesti G and Mannucci E: Safety issues with
glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic
cancer and cholelithiasis): Data from randomized controlled trials.
Diabetes Obes Metab. 19:1233–1241. 2017.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Zhao HJ, Jiang X, Hu LJ, Yang L, Deng LD,
Wang YP and Ren ZP: Activation of GLP-1 receptor enhances the
chemosensitivity of pancreatic cancer cells. J Mol Endocrinol.
64:103–113. 2020.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Mao D, Cao H, Shi M, Wang CC, Kwong J, Li
JJX, Hou Y, Ming X, Lee HM, Tian XY, et al: Increased co-expression
of PSMA2 and GLP-1 receptor in cervical cancer models in type 2
diabetes attenuated by exendin-4: A translational case-control
study. EBioMedicine. 65(103242)2021.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Zhang Y, Cheng J, Li J, He J, Li X and Xu
F: The GLP-1R agonist exendin-4 attenuates hyperglycemia-induced
chemoresistance in human endometrial cancer cells through
ROS-mediated mitochondrial pathway. Front Oncol.
11(793530)2021.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Li W, Gu Y, Liu S, Ruan F and Lv W: GLP1R
inhibits the progression of endometrial carcinoma through
activation of cAMP/PKA pathway. J Clin Lab Anal.
36(e24604)2022.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Byrd RA, Sorden SD, Ryan T, Pienkowski T,
LaRock R, Quander R, Wijsman JA, Smith HW, Blackbourne JL, Rosol
TJ, et al: Chronic toxicity and carcinogenicity studies of the
long-acting GLP-1 receptor agonist dulaglutide in rodents.
Endocrinology. 156:2417–2428. 2015.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Mao T, Zhang C, Yang S, Bi Y, Li M and Yu
J: Semaglutide alters gut microbiota and improves NAFLD in db/db
mice. Biochem Biophys Res Commun. 710(149882)2024.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Chen BD, Zhao WC, Jia QA, Zhou WY, Bu Y,
Wang ZZ, Wang F, Wu WJ and Wang Q: Effect of the GLP-1 analog
exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell
line and mouse model. Int J Mol Sci. 14:24293–24304.
2013.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Kissow H, Hartmann B, Holst JJ, Viby NE,
Hansen LS, Rosenkilde MM, Hare KJ and Poulsen SS: Glucagon-like
peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not
accelerate neoplasia in carcinogen treated mice. Regul Pept.
179:91–100. 2012.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Iwaya C, Nomiyama T, Komatsu S, Kawanami
T, Tsutsumi Y, Hamaguchi Y, Horikawa T, Yoshinaga Y, Yamashita S,
Tanaka T, et al: Exendin-4, a glucagonlike peptide-1 receptor
agonist, attenuates breast cancer growth by inhibiting NF-κB
activation. Endocrinology. 158:4218–4232. 2017.PubMed/NCBI View Article : Google Scholar
|
|
190
|
Ligumsky H, Amir S, Arbel Rubinstein T,
Guion K, Scherf T, Karasik A, Wolf I and Rubinek T: Glucagon-like
peptide-1 analogs activate AMP kinase leading to reversal of the
Warburg metabolic switch in breast cancer cells. Med Oncol.
41(138)2024.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Dai H, Li Y, Lee YA, Lu Y, George TJ,
Donahoo WT, Lee KP, Nakshatri H, Allen J, Guo Y, et al: GLP-1
receptor agonists and cancer risk in adults with obesity. JAMA
Oncol. 11:1186–1193. 2025.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Pasternak B, Wintzell V, Hviid A, Eliasson
B, Gudbjörnsdottir S, Jonasson C, Hveem K, Svanström H, Melbye M
and Ueda P: Glucagon-like peptide 1 receptor agonist use and risk
of thyroid cancer: Scandinavian cohort study. BMJ.
385(e078225)2024.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Bezin J, Gouverneur A, Pénichon M, Mathieu
C, Garrel R, Hillaire-Buys D, Pariente A and Faillie JL: GLP-1
receptor agonists and the risk of thyroid cancer. Diabetes Care.
46:384–390. 2023.PubMed/NCBI View Article : Google Scholar
|
|
194
|
Feier CVI, Vonica RC, Faur AM, Streinu DR
and Muntean C: Assessment of thyroid carcinogenic risk and safety
profile of GLP1-RA semaglutide (ozempic) therapy for diabetes
mellitus and obesity: A systematic literature review. Int J Mol
Sci. 25(4346)2024.PubMed/NCBI View Article : Google Scholar
|
|
195
|
Newsome PN, Buchholtz K, Cusi K, Linder M,
Okanoue T, Ratziu V, Sanyal AJ, Sejling AS and Harrison SA:
NN9931-4296 Investigators. A placebo-controlled trial of
subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J
Med. 384:1113–1124. 2021.PubMed/NCBI View Article : Google Scholar
|
|
196
|
Abrahami D, Yin H, Yu OHY, Pollak MN and
Azoulay L: Incretin-based drugs and the incidence of colorectal
cancer in patients with type 2 diabetes. Epidemiology. 29:246–253.
2018.PubMed/NCBI View Article : Google Scholar
|
|
197
|
Figlioli G, Piovani D, Peppas S, Pugliese
N, Hassan C, Repici A, Lleo A, Aghemo A and Bonovas S:
Glucagon-like peptide-1 receptor agonists and risk of
gastrointestinal cancers: A systematic review and meta-analysis of
randomized controlled trials. Pharmacol Res.
208(107401)2024.PubMed/NCBI View Article : Google Scholar
|
|
198
|
Piccoli GF, Mesquita LA, Stein C, Aziz M,
Zoldan M, Degobi NAH, Spiazzi BF, Lopes Junior GL, Colpani V and
Gerchman F: Do GLP-1 receptor agonists increase the risk of breast
cancer? A systematic review and meta-analysis. J Clin Endocrinol
Metab. 106:912–921. 2021.PubMed/NCBI View Article : Google Scholar
|
|
199
|
Sun Y, Liu Y, Dian Y, Zeng F, Deng G and
Lei S: Association of glucagon-like peptide-1 receptor agonists
with risk of cancers-evidence from a drug target Mendelian
randomization and clinical trials. Int J Surg. 110:4688–4694.
2024.PubMed/NCBI View Article : Google Scholar
|
|
200
|
Wang L, Wang Q, Li L, Kaelber DC and Xu R:
Glucagon-like peptide-1 receptor agonists and pancreatic cancer
risk: Target trial emulation using real-world data. J Natl Cancer
Inst. 117:476–485. 2025.PubMed/NCBI View Article : Google Scholar
|
|
201
|
Bjerre Knudsen L, Madsen LW, Andersen S,
Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL,
Hegelund AC, Jacobsen H, et al: Glucagon-like peptide-1 receptor
agonists activate rodent thyroid C-cells causing calcitonin release
and C-cell proliferation. Endocrinology. 151:1473–1486.
2010.PubMed/NCBI View Article : Google Scholar
|
|
202
|
He L, Zhang S, Zhang X, Liu R, Guan H and
Zhang H: Effects of insulin analogs and glucagon-like peptide-1
receptor agonists on proliferation and cellular energy metabolism
in papillary thyroid cancer. Onco Targets Ther. 10:5621–5631.
2017.PubMed/NCBI View Article : Google Scholar
|
|
203
|
Sherman SI, Kloos RT, Tuttle RM,
Pontecorvi A, Völzke H, Harper K, Vance C, Alston JT, Usborne AL,
Sloop KW and Lakshmanan M: No calcitonin change in a person taking
dulaglutide diagnosed with pre-existing medullary thyroid cancer.
Diabet Med. 35:381–385. 2018.PubMed/NCBI View Article : Google Scholar
|
|
204
|
Wang J and Kim CH: Differential risk of
cancer associated with glucagon-like peptide-1 receptor agonists:
Analysis of real-world databases. Endocr Res. 47:18–25.
2022.PubMed/NCBI View Article : Google Scholar
|
|
205
|
Espinosa De Ycaza AE, Brito JP, McCoy RG,
Shao H and Singh Ospina N: Glucagon-like peptide-1 receptor
agonists and thyroid cancer: A narrative review. Thyroid.
34:403–418. 2024.PubMed/NCBI View Article : Google Scholar
|
|
206
|
Koehler JA and Drucker DJ: Activation of
glucagon-like peptide-1 receptor signaling does not modify the
growth or apoptosis of human pancreatic cancer cells. Diabetes.
55:1369–1379. 2006.PubMed/NCBI View Article : Google Scholar
|
|
207
|
Kojima M, Takahashi H, Kuwashiro T, Tanaka
K, Mori H, Ozaki I, Kitajima Y, Matsuda Y, Ashida K, Eguchi Y and
Anzai K: Glucagon-like peptide-1 receptor agonist prevented the
progression of hepatocellular carcinoma in a mouse model of
nonalcoholic steatohepatitis. Int J Mol Sci.
21(5722)2020.PubMed/NCBI View Article : Google Scholar
|
|
208
|
Sun Y, Fan L, Meng J, Zhang F, Zhang D and
Mei Q: Should GLP-1 receptor agonists be used with caution in high
risk population for colorectal cancer? Med Hypotheses. 82:255–256.
2014.PubMed/NCBI View Article : Google Scholar
|
|
209
|
Elsaid MI, Li N, Firkins SA, Rustgi VK,
Paskett ED, Acharya C, Reddy KR, Chiang CW and Mumtaz K: Impacts of
glucagon-like peptide-1 receptor agonists on the risk of adverse
liver outcomes in patients with metabolic dysfunction-associated
steatotic liver disease cirrhosis and type 2 diabetes. Aliment
Pharmacol Ther. 59:1096–1110. 2024.PubMed/NCBI View Article : Google Scholar
|
|
210
|
Tong G, Peng T, Chen Y, Sha L, Dai H,
Xiang Y, Zou Z, He H and Wang S: Effects of GLP-1 receptor agonists
on biological behavior of colorectal cancer cells by regulating
PI3K/AKT/mTOR signaling pathway. Front Pharmacol.
13(901559)2022.PubMed/NCBI View Article : Google Scholar
|
|
211
|
Ma B, Wang X, Ren H, Li Y, Zhang H, Yang M
and Li J: High glucose promotes the progression of colorectal
cancer by activating the BMP4 signaling and inhibited by
glucagon-like peptide-1 receptor agonist. BMC Cancer.
23(594)2023.PubMed/NCBI View Article : Google Scholar
|
|
212
|
Zhu C, Lai Y, Liu C, Teng L, Zhu Y, Lin X,
Fu X, Lai Q, Liu S, Zhou X and Fang Y: Comprehensively prognostic
and immunological analyses of GLP-1 signaling-related genes in
pan-cancer and validation in colorectal cancer. Front Pharmacol.
15(1387243)2024.PubMed/NCBI View Article : Google Scholar
|
|
213
|
Xu Y, Ni F, Sun D, Peng Y, Zhao Y, Wu X,
Li S, Qi X, He X, Li M, et al: Glucagon enhances chemotherapy
efficacy by inhibition of tumor vessels in colorectal cancer. Adv
Sci (Weinh). 11(e2307271)2024.PubMed/NCBI View Article : Google Scholar
|
|
214
|
Hagemann AR, Hagemann IS, Mutch DG, Devor
EJ, Malmrose PK, Zhang Y, Morrison AM, Thiel KW and Leslie KK:
Enhancing progestin therapy with a glucagon-like peptide 1 agonist
for the conservative management of endometrial cancer. Cancers
(Basel). 17(598)2025.PubMed/NCBI View Article : Google Scholar
|
|
215
|
Bułdak Ł, Machnik G, Bułdak RJ, Łabuzek K,
Bołdys A, Belowski D, Basiak M and Okopień B: Exenatide (a GLP-1
agonist) expresses anti-inflammatory properties in cultured human
monocytes/macrophages in a protein kinase A and B/Akt manner.
Pharmacol Rep. 68:329–337. 2016.PubMed/NCBI View Article : Google Scholar
|
